{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:28:41Z","timestamp":1790425721876,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Silent corticotrophic adenomas (SCAs) represent a rare group of non-functioning adenomas with a potentially aggressive clinical course. Cystic component is a very common finding among SCAs, but its clinical relevance has not yet been investigated. The aim of this study was to analyze clinical features of cystic and non-cystic SCAs, perioperative complications after microscopic transsphenoidal surgery, clinical outcome after first and repeat surgery along with risk factors for recurrence. We conducted a retrospective analysis of 62 silent corticotrophic adenomas treated at our university medical center via microscopic transsphenoidal surgery between January 2008 and July 2019. Parameters investigated included histology, invasiveness, intratumoral haemorrhage or cystic component on MRI, perioperative alteration of visual field, tumor size, pre- and postoperative ACTH, FSH, GH, LH, TSH, prolactin, cortisol, free T4, free T3, IGF-1, estrogen and testosterone levels, perioperative complications, neoadjuvant and adjuvant therapy along with clinical outcomes. A total of 62 patients were analyzed. The mean follow up was 28.3\u00a0months. Tumors with a cystic component occur statistically significant more often among male than non-cystic (80.6% vs. 44.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02) and display lower rates of cavernous sinus invasion and sphenoid sinus invasion were significantly lower for cystic lesions comparing to non-cystic tumors (42.3% vs. 69.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04 and 3.8% vs. 47.2%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). GTR after MTS was not statistically significant higher by cystic SCAs (80% vs. 57.1%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.09). Cystic lesions were also associated with higher risk of hyperprolactinemia (19.4% vs. 2.8%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02) and only densely granulated cystic SCAs presented with preoperative intratumoral hemorrhage (19.2% vs. 0%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01). Mean duration of first surgery was significantly shorter for cystic SCAs (71.6(\u00b1\u200918.7) vs. 94.8(\u00b1\u200931.1) minutes,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01). Preoperative pituitary insufficiency (25% vs. 16.7%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.49), intraoperative CSF space opening (21.1% vs. 37.5%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.32), along with postoperative new pituitary insufficiency (15% vs. 10%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.67) or diabetes insipidus\/SIADH (10% vs. 13.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.99) with histological markers such as Ki67 (21.1% vs. 13.8%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.70) and p53 expression (6.3% vs. 0%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.39) as well as mitotic rate (5.3% vs. 10.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.99) were comparable between both groups. The presence of cystic component did not affect the tumor recurrence (10% vs. 16%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.68). Mean duration of surgery was first surgeries was not statistically shorter than repeat surgeries (85.4\u2009\u00b1\u200929.1 vs. 93.8\u2009\u00b1\u200928\u00a0min,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.15). Patients undergoing first surgery had a higher probability of gross total resection (74.4% vs. 30%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01) and lower probability of intraoperative CSF space opening (26% vs. 58.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04) as well as a lower rate of preoperative anterior pituitary insufficiency (20% vs. 58.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01). The incidence of new postoperative anterior pituitary insufficiency (10% vs. 0%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.57) and transient diabetes insipidus\/SIADH (12% vs. 8.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.99) between those groups were comparable. No statistical difference was observed between patients with remission and with recurrent tumor regarding cortisol and ACTH levels, incidence of different histological subgroups, invasively growing tumors and lesions with cystic components as well as the percentage of cases with increased Ki67 proliferation index, p53 expression and mitotic indices. Our study presents one of the largest available cohorts of SCAs after microscopic transsphenoidal surgery and first clinical analysis of cystic versus non-cystic SCAs so far. We also performed the first comparison of index and repeat surgeries for this tumor entity. Cystic tumors presented with characteristic clinical aspects like male predominance, higher risk of hyperprolactinemia as well as lower rates of cavernous sinus and sphenoid sinus invasion comparing to non-cystic lesions. Mean duration of first surgery was significantly shorter for cystic SCAs. Moreover preoperative intratumoral hemorrhage had 100% specificity and 60% sensitivity for densely granulated cystic SCAs. All these clinical hallmarks may suggest a novel subgroup of SCAs with distinct clinical and biological features, however further clinical and molecular investigations are required. Second surgeries are associated with a higher incidence of preoperative pituitary insufficiency, and a higher risk of subtotal resection, and a higher probability of CSF space opening intraoperatively compared to first surgeries. On the other hand, the risk of new postoperative pituitary insufficiency was higher after first surgeries. In our cohort of patients, no prognostic factor for recurrence among histological diagnosis, Ki67-proliferation index, p53 expression, number of mitoses, invasive growth or cystic lesions for SCAs could be detected.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-29628-3","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T05:03:45Z","timestamp":1676091825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery\u2014a retrospective, single-center study"],"prefix":"10.1038","volume":"13","author":[{"given":"Piotr","family":"Sumislawski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torge","family":"Huckhagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara Leigh","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Saeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Flitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rotermund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,11]]},"reference":[{"issue":"2","key":"29628_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/S11102-014-0624-3","volume":"18","author":"O Cooper","year":"2014","unstructured":"Cooper, O. Silent corticotroph adenomas. Pituitary 18(2), 225\u2013231. https:\/\/doi.org\/10.1007\/S11102-014-0624-3 (2014).","journal-title":"Pituitary"},{"issue":"7","key":"29628_CR2","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1210\/JC.2018-00688","volume":"104","author":"J Drummond","year":"2019","unstructured":"Drummond, J., Roncaroli, F., Grossman, A. B. & Korbonits, M. Clinical and pathological aspects of silent pituitary adenomas. J Clin Endocrinol Metab. 104(7), 2473\u20132489. https:\/\/doi.org\/10.1210\/JC.2018-00688 (2019).","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"29628_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/EJE.1.02326","volume":"156","author":"W Saeger","year":"2007","unstructured":"Saeger, W. et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 156(2), 203\u2013216. https:\/\/doi.org\/10.1530\/EJE.1.02326 (2007).","journal-title":"Eur J Endocrinol."},{"key":"29628_CR4","unstructured":"Drummond, J.B., Ant\u00f4nio Ribeiro-Oliveira, J. & Soares, B. S. Non-Functioning Pituitary Adenomas. Published online November 28, 2018. Accessed October 22, 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534880\/"},{"key":"29628_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2020.608691","author":"K Zhang","year":"2021","unstructured":"Zhang, K. et al. Clinical parameters of silent corticotroph adenomas with positive and negative adrenocorticotropic hormone immunostaining: a large retrospective single-center study of 105 cases. Front Endocrinol (Lausanne) https:\/\/doi.org\/10.3389\/FENDO.2020.608691 (2021).","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"29628_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/S12022-015-9398-Z","volume":"26","author":"H Nishioka","year":"2015","unstructured":"Nishioka, H. et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr. Pathol. 26(4), 349\u2013355. https:\/\/doi.org\/10.1007\/S12022-015-9398-Z (2015).","journal-title":"Endocr. Pathol."},{"issue":"4","key":"29628_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/S00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes, M. B. S. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 134(4), 521\u2013535. https:\/\/doi.org\/10.1007\/S00401-017-1769-8 (2017).","journal-title":"Acta Neuropathol."},{"issue":"3","key":"29628_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1385\/EP:13:3:245","volume":"13","author":"F Roncaroli","year":"2002","unstructured":"Roncaroli, F., Faustini-Fustini, M., Mauri, F., Asioli, S. & Frank, G. Crooke\u2019s hyalinization in silent corticotroph adenoma: Report of two cases. Endocr. Pathol. 13(3), 245\u2013249. https:\/\/doi.org\/10.1385\/EP:13:3:245 (2002).","journal-title":"Endocr. Pathol."},{"issue":"4","key":"29628_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/S12022-013-9270-Y","volume":"24","author":"O Mete","year":"2013","unstructured":"Mete, O. et al. The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. Endocr. Pathol. 24(4), 191\u2013198. https:\/\/doi.org\/10.1007\/S12022-013-9270-Y (2013).","journal-title":"Endocr. Pathol."},{"issue":"1","key":"29628_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1227\/01.NEU.0000429858.96652.1E","volume":"73","author":"A Jahangiri","year":"2013","unstructured":"Jahangiri, A. et al. A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73(1), 8\u201318. https:\/\/doi.org\/10.1227\/01.NEU.0000429858.96652.1E (2013).","journal-title":"Neurosurgery"},{"issue":"9","key":"29628_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1055\/s-2007-984437","volume":"115","author":"T Psaras","year":"2007","unstructured":"Psaras, T. et al. Atypical type II silent corticotrophic adenoma developing into Cushing\u2019s disease upon second recurrence. Exp. Clin. Endocrinol. Diabetes 115(9), 610\u2013615. https:\/\/doi.org\/10.1055\/s-2007-984437 (2007).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"1","key":"29628_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/S11102-017-0844-4","volume":"21","author":"F Langlois","year":"2018","unstructured":"Langlois, F. et al. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary 21(1), 32\u201340. https:\/\/doi.org\/10.1007\/S11102-017-0844-4 (2018).","journal-title":"Pituitary"},{"issue":"23","key":"29628_CR13","doi-asserted-by":"publisher","first-page":"6134","DOI":"10.3390\/cancers13236134","volume":"13","author":"S Jiang","year":"2021","unstructured":"Jiang, S., Chen, X., Wu, Y., Wang, R. & Bao, X. An update on silent corticotroph adenomas: Diagnosis, mechanisms, clinical features, and management. Cancers (Basel). 13(23), 6134. https:\/\/doi.org\/10.3390\/cancers13236134 (2021).","journal-title":"Cancers (Basel)."},{"issue":"4","key":"29628_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/cen.12443","volume":"81","author":"L Cazabat","year":"2014","unstructured":"Cazabat, L. et al. Silent, but not unseen: Multimicrocystic aspect on T2-weighted MRI in silent corticotroph adenomas. Clin. Endocrinol. (Oxf.) 81(4), 566\u2013572. https:\/\/doi.org\/10.1111\/cen.12443 (2014).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"29628_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14133","author":"L Kasuki","year":"2020","unstructured":"Kasuki, L. et al. Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas. Clin. Endocrinol. (Oxf). https:\/\/doi.org\/10.1111\/cen.14133 (2020).","journal-title":"Clin. Endocrinol. (Oxf)."},{"issue":"6","key":"29628_CR16","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.3892\/etm.2017.4299","volume":"13","author":"D Xiao","year":"2017","unstructured":"Xiao, D. et al. Fluid-fluid level on magnetic resonance images may predict the occurrence of pituitary adenomas in cystic sellar-suprasellar masses. Exp. Ther. Med. 13(6), 3123\u20133129. https:\/\/doi.org\/10.3892\/etm.2017.4299 (2017).","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"29628_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3346\/JKMS.2005.20.3.489","volume":"20","author":"KI Paek","year":"2005","unstructured":"Paek, K. I. et al. Clinical significance of Ki-67 Labeling Index in pituitary macroadenoma. J. Korean Med. Sci. 20(3), 489. https:\/\/doi.org\/10.3346\/JKMS.2005.20.3.489 (2005).","journal-title":"J. Korean Med. Sci."},{"issue":"4","key":"29628_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1227\/00006123-199604000-00027","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar, K., Scheithauer, B. W., Kovacs, K., Pernicone, P. J. & Laws, E. R. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38(4), 765\u2013771. https:\/\/doi.org\/10.1227\/00006123-199604000-00027 (1996).","journal-title":"Neurosurgery"},{"issue":"18","key":"29628_CR19","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.7150\/JCA.20935","volume":"8","author":"X Ma","year":"2017","unstructured":"Ma, X. et al. Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases. J. Cancer 8(18), 3828. https:\/\/doi.org\/10.7150\/JCA.20935 (2017).","journal-title":"J. Cancer"},{"issue":"39","key":"29628_CR20","doi-asserted-by":"publisher","first-page":"65064","DOI":"10.18632\/ONCOTARGET.17775","volume":"8","author":"JY Kim","year":"2017","unstructured":"Kim, J. Y. et al. The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67. Oncotarget 8(39), 65064. https:\/\/doi.org\/10.18632\/ONCOTARGET.17775 (2017).","journal-title":"Oncotarget"},{"key":"29628_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12022-021-09693-Y","volume":"1","author":"W Saeger","year":"2021","unstructured":"Saeger, W., Mawrin, C., Meinhardt, M., Wefers, A. K. & Jacobsen, F. Two pituitary neuroendocrine tumors (PitNETs) with very high proliferation and TP53 mutation\u2014High-grade PitNET or PitNEC?. Endocr. Pathol. 1, 1\u20136. https:\/\/doi.org\/10.1007\/S12022-021-09693-Y (2021).","journal-title":"Endocr. Pathol."},{"key":"29628_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/S40478-015-0229-8","volume":"3","author":"CP Miermeister","year":"2015","unstructured":"Miermeister, C. P. et al. Histological criteria for atypical pituitary adenomas\u2014Data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol. Commun. 3, 50. https:\/\/doi.org\/10.1186\/S40478-015-0229-8 (2015).","journal-title":"Acta Neuropathol. Commun."},{"issue":"3\u20134","key":"29628_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000095533","volume":"83","author":"DK L\u00fcdecke","year":"2006","unstructured":"L\u00fcdecke, D. K. & Abe, T. Transsphenoidal microsurgery for newly diagnosed acromegaly: A personal view after more than 1,000 operations. Neuroendocrinology 83(3\u20134), 230\u2013239. https:\/\/doi.org\/10.1159\/000095533 (2006).","journal-title":"Neuroendocrinology"},{"issue":"6","key":"29628_CR24","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.3171\/2020.3.FOCUS2061","volume":"48","author":"R Rotermund","year":"2020","unstructured":"Rotermund, R. et al. Real-life analysis of 280 patients with surgically treated acromegaly: A single-center experience from 2008 to 2015. Neurosurg. Focus. 48(6), E9. https:\/\/doi.org\/10.3171\/2020.3.FOCUS2061 (2020).","journal-title":"Neurosurg. Focus."},{"issue":"1","key":"29628_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3340\/JKNS.2018.0027","volume":"62","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Clinical significance of radical surgery in the treatment of silent corticotroph adenoma. J. Korean Neurosurg Soc. 62(1), 114\u2013122. https:\/\/doi.org\/10.3340\/JKNS.2018.0027 (2019).","journal-title":"J. Korean Neurosurg Soc."},{"issue":"6","key":"29628_CR26","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/J.CLINEURO.2004.12.004","volume":"107","author":"B Schaller","year":"2005","unstructured":"Schaller, B. Trigemino-cardiac reflex during transsphenoidal surgery for pituitary adenomas. Clin. Neurol. Neurosurg. 107(6), 468\u2013474. https:\/\/doi.org\/10.1016\/J.CLINEURO.2004.12.004 (2005).","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"5","key":"29628_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3325\/CMJ.2020.61.410","volume":"61","author":"T \u010ces\u00e1k","year":"2020","unstructured":"\u010ces\u00e1k, T. et al. Microsurgical versus endoscopic surgery for non-functioning pituitary adenomas: a retrospective study. Croat Med. J. 61(5), 410\u2013421. https:\/\/doi.org\/10.3325\/CMJ.2020.61.410 (2020).","journal-title":"Croat Med. J."},{"key":"29628_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-00960-0","author":"D Esposito","year":"2019","unstructured":"Esposito, D. et al. Non-functioning pituitary adenomas: Indications for pituitary surgery and post-surgical management. Pituitary https:\/\/doi.org\/10.1007\/s11102-019-00960-0 (2019).","journal-title":"Pituitary"},{"issue":"3","key":"29628_CR29","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1111\/jcmm.13445","volume":"22","author":"SY Yu","year":"2018","unstructured":"Yu, S. Y. et al. Outcomes of endoscopic and microscopic transsphenoidal surgery on non-functioning pituitary adenomas: A systematic review and meta-analysis. J Cell Mol Med. 22(3), 2023\u20132027. https:\/\/doi.org\/10.1111\/jcmm.13445 (2018).","journal-title":"J Cell Mol Med."},{"key":"29628_CR30","doi-asserted-by":"publisher","first-page":"614382","DOI":"10.3389\/FNEUR.2021.614382","volume":"12","author":"S Guo","year":"2021","unstructured":"Guo, S., Wang, Z., Kang, X., Xin, W. & Li, X. A meta-analysis of endoscopic vs. microscopic transsphenoidal surgery for non-functioning and functioning pituitary adenomas: comparisons of efficacy and safety. Front Neurol. 12, 614382. https:\/\/doi.org\/10.3389\/FNEUR.2021.614382 (2021).","journal-title":"Front Neurol."},{"issue":"4","key":"29628_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11102-013-0502-4","volume":"17","author":"A Paluzzi","year":"2014","unstructured":"Paluzzi, A. et al. Endoscopic endonasal approach for pituitary adenomas: A series of 555 patients. Pituitary 17(4), 307\u2013319. https:\/\/doi.org\/10.1007\/s11102-013-0502-4 (2014).","journal-title":"Pituitary"},{"issue":"2","key":"29628_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3171\/2016.8.JNS152709","volume":"127","author":"HM Negm","year":"2017","unstructured":"Negm, H. M. et al. Reoperative endoscopic endonasal surgery for residual or recurrent pituitary adenomas. J Neurosurg. 127(2), 397\u2013408. https:\/\/doi.org\/10.3171\/2016.8.JNS152709 (2017).","journal-title":"J Neurosurg."},{"issue":"3","key":"29628_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11102-010-0221-z","volume":"13","author":"EF Chang","year":"2010","unstructured":"Chang, E. F. et al. Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas. Pituitary 13(3), 223\u2013229. https:\/\/doi.org\/10.1007\/s11102-010-0221-z (2010).","journal-title":"Pituitary"},{"issue":"6","key":"29628_CR34","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3171\/jns.2005.102.6.1004","volume":"102","author":"RJ Benveniste","year":"2005","unstructured":"Benveniste, R. J. et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J. Neurosurg. 102(6), 1004\u20131012. https:\/\/doi.org\/10.3171\/jns.2005.102.6.1004 (2005).","journal-title":"J. Neurosurg."},{"issue":"1","key":"29628_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/02688690500081230","volume":"19","author":"SE Baldeweg","year":"2005","unstructured":"Baldeweg, S. E., Pollock, J. R., Powell, M. & Ahlquist, J. A spectrum of behaviour in silent corticotroph pituitary adenomas. Br. J. Neurosurg. 19(1), 38\u201342. https:\/\/doi.org\/10.1080\/02688690500081230 (2005).","journal-title":"Br. J. Neurosurg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29628-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T08:19:16Z","timestamp":1676276356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29628-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["29628"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-29628-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,11]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2468"}}